Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting
There is growing evidence from in vitro studies that subgroup B adenoviruses (Ad) can overcome the limitations in safety and tumor transduction efficiency seen with commonly used subgroup C serotype 5-based vectors. In this study, we confirm that the expression level of the B-group Ad receptor, CD46...
Gespeichert in:
| Veröffentlicht in: | Cancer gene therapy 2006-12, Vol.13 (12), p.1072-1081 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1081 |
|---|---|
| container_issue | 12 |
| container_start_page | 1072 |
| container_title | Cancer gene therapy |
| container_volume | 13 |
| creator | Ni, S Gaggar, A Di Paolo, N Li, Z Y Liu, Y Strauss, R Sova, P Morihara, J Feng, Q Kiviat, N Touré, P Sow, P S Lieber, A |
| description | There is growing evidence from
in vitro
studies that subgroup B adenoviruses (Ad) can overcome the limitations in safety and tumor transduction efficiency seen with commonly used subgroup C serotype 5-based vectors. In this study, we confirm that the expression level of the B-group Ad receptor, CD46, correlates with the grade of malignancy of cervical cancer
in situ
. We also demonstrate the
in vivo
properties of Ad5-based vectors that contain the B-group Ad serotype 35 fiber (Ad5/35) in transgenic mice that express CD46 in a pattern and at a level similar to humans. Upon intravenous and intraperitoneal injection, an Ad5/35 vector did not efficiently transduce normal tissue, but was able to target metastatic or intraperitoneal tumors that express CD46 at levels comparable to human tumors. When an oncolytic Ad5/35-based vector was employed, in both tumor models antitumor effects were observed. Furthermore, injection of Ad5/35 vectors into CD46 transgenic mice caused less innate toxicity than Ad5 vectors. Our data demonstrate that Ad vectors that target CD46 offer advantages over Ad5-based vectors for treatment of cancer. |
| doi_str_mv | 10.1038/sj.cgt.7700981 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_19730598</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A182635971</galeid><sourcerecordid>A182635971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c645t-35d9430669d234260ffb52f6113cc4afa14b9f4f73adb80d8c2f88b768b7e0e73</originalsourceid><addsrcrecordid>eNp1kttrFDEYxYModq2--qYMCn2bbW6Ty2Mp9QIFQfQ5ZDLJNMtMsiaZhf73zbKrq9ISkkDO75zcPgDeIrhGkIjLvFmbsaw5h1AK9AysEOWs7ToIn4MVlFi2SEJyBl7lvIGwipy8BGeICU4JQyvw_Wanp0UXH0MTXaMHG-LOpyU3O2tKTLkxMRTtgw9jk22K5X5rG9I1zve2qi6mpizzftRptKVir8ELp6ds3xznc_Dz082P6y_t7bfPX6-vblvDaFda0g2SEsiYHDChmEHn-g47hhAxhmqnEe2lo44TPfQCDsJgJ0TPWe0WWk7OwcUhd5vir8XmomafjZ0mHWxcskKSE9hJUcGP_4GbuKRQz6Ywo4hjQgiu1IcnKcSp6DCFp6hRT1b54GJJ2uz3VVdIYEY6yVGl1o9QtQ129vU9rfN1_R_DxV-GO6uncpfjtOy_JT-abFLMOVmntsnPOt0rBNW-IFTeqFoQ6lgQ1fD-eKuln-1wwo8VUIHLA5CrFEabTtd-MvLdwRF0WZL9E_lbfwBAxchL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217485240</pqid></control><display><type>article</type><title>Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Ni, S ; Gaggar, A ; Di Paolo, N ; Li, Z Y ; Liu, Y ; Strauss, R ; Sova, P ; Morihara, J ; Feng, Q ; Kiviat, N ; Touré, P ; Sow, P S ; Lieber, A</creator><creatorcontrib>Ni, S ; Gaggar, A ; Di Paolo, N ; Li, Z Y ; Liu, Y ; Strauss, R ; Sova, P ; Morihara, J ; Feng, Q ; Kiviat, N ; Touré, P ; Sow, P S ; Lieber, A</creatorcontrib><description>There is growing evidence from
in vitro
studies that subgroup B adenoviruses (Ad) can overcome the limitations in safety and tumor transduction efficiency seen with commonly used subgroup C serotype 5-based vectors. In this study, we confirm that the expression level of the B-group Ad receptor, CD46, correlates with the grade of malignancy of cervical cancer
in situ
. We also demonstrate the
in vivo
properties of Ad5-based vectors that contain the B-group Ad serotype 35 fiber (Ad5/35) in transgenic mice that express CD46 in a pattern and at a level similar to humans. Upon intravenous and intraperitoneal injection, an Ad5/35 vector did not efficiently transduce normal tissue, but was able to target metastatic or intraperitoneal tumors that express CD46 at levels comparable to human tumors. When an oncolytic Ad5/35-based vector was employed, in both tumor models antitumor effects were observed. Furthermore, injection of Ad5/35 vectors into CD46 transgenic mice caused less innate toxicity than Ad5 vectors. Our data demonstrate that Ad vectors that target CD46 offer advantages over Ad5-based vectors for treatment of cancer.</description><identifier>ISSN: 0929-1903</identifier><identifier>EISSN: 1476-5500</identifier><identifier>DOI: 10.1038/sj.cgt.7700981</identifier><identifier>PMID: 16874361</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Adenoviridae - genetics ; Adenovirus ; Adenoviruses ; Adenoviruses, Human ; Animals ; Antitumor activity ; Biomedical and Life Sciences ; Biomedicine ; CD46 antigen ; Cell Line, Tumor ; Cervical cancer ; Cervix ; Chemokines - blood ; Control ; CpG Islands ; Cytokines - blood ; DNA Methylation ; Expression vectors ; Female ; Gene Expression ; Gene Therapy ; Genetic aspects ; Genetic Therapy - methods ; Genetic Vectors - genetics ; Genetic Vectors - pharmacokinetics ; Genetic Vectors - pharmacology ; Growth ; Health aspects ; Humans ; Inflammation - immunology ; Inflammation - metabolism ; Injection ; Intravenous administration ; Malignancy ; Membrane Cofactor Protein - genetics ; Membrane Cofactor Protein - metabolism ; Metastases ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Neoplasms - therapy ; Oncolysis ; original-article ; Physiological aspects ; Recoverin - genetics ; Recoverin - metabolism ; Tissue Distribution ; Toxicity ; Transgenic animals ; Transgenic mice ; Tumors ; Uterine Cervical Neoplasms - immunology</subject><ispartof>Cancer gene therapy, 2006-12, Vol.13 (12), p.1072-1081</ispartof><rights>Springer Nature America, Inc. 2006</rights><rights>COPYRIGHT 2006 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Dec 2006</rights><rights>Nature Publishing Group 2006.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c645t-35d9430669d234260ffb52f6113cc4afa14b9f4f73adb80d8c2f88b768b7e0e73</citedby><cites>FETCH-LOGICAL-c645t-35d9430669d234260ffb52f6113cc4afa14b9f4f73adb80d8c2f88b768b7e0e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16874361$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ni, S</creatorcontrib><creatorcontrib>Gaggar, A</creatorcontrib><creatorcontrib>Di Paolo, N</creatorcontrib><creatorcontrib>Li, Z Y</creatorcontrib><creatorcontrib>Liu, Y</creatorcontrib><creatorcontrib>Strauss, R</creatorcontrib><creatorcontrib>Sova, P</creatorcontrib><creatorcontrib>Morihara, J</creatorcontrib><creatorcontrib>Feng, Q</creatorcontrib><creatorcontrib>Kiviat, N</creatorcontrib><creatorcontrib>Touré, P</creatorcontrib><creatorcontrib>Sow, P S</creatorcontrib><creatorcontrib>Lieber, A</creatorcontrib><title>Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting</title><title>Cancer gene therapy</title><addtitle>Cancer Gene Ther</addtitle><addtitle>Cancer Gene Ther</addtitle><description>There is growing evidence from
in vitro
studies that subgroup B adenoviruses (Ad) can overcome the limitations in safety and tumor transduction efficiency seen with commonly used subgroup C serotype 5-based vectors. In this study, we confirm that the expression level of the B-group Ad receptor, CD46, correlates with the grade of malignancy of cervical cancer
in situ
. We also demonstrate the
in vivo
properties of Ad5-based vectors that contain the B-group Ad serotype 35 fiber (Ad5/35) in transgenic mice that express CD46 in a pattern and at a level similar to humans. Upon intravenous and intraperitoneal injection, an Ad5/35 vector did not efficiently transduce normal tissue, but was able to target metastatic or intraperitoneal tumors that express CD46 at levels comparable to human tumors. When an oncolytic Ad5/35-based vector was employed, in both tumor models antitumor effects were observed. Furthermore, injection of Ad5/35 vectors into CD46 transgenic mice caused less innate toxicity than Ad5 vectors. Our data demonstrate that Ad vectors that target CD46 offer advantages over Ad5-based vectors for treatment of cancer.</description><subject>Adenoviridae - genetics</subject><subject>Adenovirus</subject><subject>Adenoviruses</subject><subject>Adenoviruses, Human</subject><subject>Animals</subject><subject>Antitumor activity</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>CD46 antigen</subject><subject>Cell Line, Tumor</subject><subject>Cervical cancer</subject><subject>Cervix</subject><subject>Chemokines - blood</subject><subject>Control</subject><subject>CpG Islands</subject><subject>Cytokines - blood</subject><subject>DNA Methylation</subject><subject>Expression vectors</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Gene Therapy</subject><subject>Genetic aspects</subject><subject>Genetic Therapy - methods</subject><subject>Genetic Vectors - genetics</subject><subject>Genetic Vectors - pharmacokinetics</subject><subject>Genetic Vectors - pharmacology</subject><subject>Growth</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Inflammation - immunology</subject><subject>Inflammation - metabolism</subject><subject>Injection</subject><subject>Intravenous administration</subject><subject>Malignancy</subject><subject>Membrane Cofactor Protein - genetics</subject><subject>Membrane Cofactor Protein - metabolism</subject><subject>Metastases</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic</subject><subject>Neoplasms - therapy</subject><subject>Oncolysis</subject><subject>original-article</subject><subject>Physiological aspects</subject><subject>Recoverin - genetics</subject><subject>Recoverin - metabolism</subject><subject>Tissue Distribution</subject><subject>Toxicity</subject><subject>Transgenic animals</subject><subject>Transgenic mice</subject><subject>Tumors</subject><subject>Uterine Cervical Neoplasms - immunology</subject><issn>0929-1903</issn><issn>1476-5500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kttrFDEYxYModq2--qYMCn2bbW6Ty2Mp9QIFQfQ5ZDLJNMtMsiaZhf73zbKrq9ISkkDO75zcPgDeIrhGkIjLvFmbsaw5h1AK9AysEOWs7ToIn4MVlFi2SEJyBl7lvIGwipy8BGeICU4JQyvw_Wanp0UXH0MTXaMHG-LOpyU3O2tKTLkxMRTtgw9jk22K5X5rG9I1zve2qi6mpizzftRptKVir8ELp6ds3xznc_Dz082P6y_t7bfPX6-vblvDaFda0g2SEsiYHDChmEHn-g47hhAxhmqnEe2lo44TPfQCDsJgJ0TPWe0WWk7OwcUhd5vir8XmomafjZ0mHWxcskKSE9hJUcGP_4GbuKRQz6Ywo4hjQgiu1IcnKcSp6DCFp6hRT1b54GJJ2uz3VVdIYEY6yVGl1o9QtQ129vU9rfN1_R_DxV-GO6uncpfjtOy_JT-abFLMOVmntsnPOt0rBNW-IFTeqFoQ6lgQ1fD-eKuln-1wwo8VUIHLA5CrFEabTtd-MvLdwRF0WZL9E_lbfwBAxchL</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>Ni, S</creator><creator>Gaggar, A</creator><creator>Di Paolo, N</creator><creator>Li, Z Y</creator><creator>Liu, Y</creator><creator>Strauss, R</creator><creator>Sova, P</creator><creator>Morihara, J</creator><creator>Feng, Q</creator><creator>Kiviat, N</creator><creator>Touré, P</creator><creator>Sow, P S</creator><creator>Lieber, A</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7QO</scope></search><sort><creationdate>20061201</creationdate><title>Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting</title><author>Ni, S ; Gaggar, A ; Di Paolo, N ; Li, Z Y ; Liu, Y ; Strauss, R ; Sova, P ; Morihara, J ; Feng, Q ; Kiviat, N ; Touré, P ; Sow, P S ; Lieber, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c645t-35d9430669d234260ffb52f6113cc4afa14b9f4f73adb80d8c2f88b768b7e0e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adenoviridae - genetics</topic><topic>Adenovirus</topic><topic>Adenoviruses</topic><topic>Adenoviruses, Human</topic><topic>Animals</topic><topic>Antitumor activity</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>CD46 antigen</topic><topic>Cell Line, Tumor</topic><topic>Cervical cancer</topic><topic>Cervix</topic><topic>Chemokines - blood</topic><topic>Control</topic><topic>CpG Islands</topic><topic>Cytokines - blood</topic><topic>DNA Methylation</topic><topic>Expression vectors</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Gene Therapy</topic><topic>Genetic aspects</topic><topic>Genetic Therapy - methods</topic><topic>Genetic Vectors - genetics</topic><topic>Genetic Vectors - pharmacokinetics</topic><topic>Genetic Vectors - pharmacology</topic><topic>Growth</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Inflammation - immunology</topic><topic>Inflammation - metabolism</topic><topic>Injection</topic><topic>Intravenous administration</topic><topic>Malignancy</topic><topic>Membrane Cofactor Protein - genetics</topic><topic>Membrane Cofactor Protein - metabolism</topic><topic>Metastases</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic</topic><topic>Neoplasms - therapy</topic><topic>Oncolysis</topic><topic>original-article</topic><topic>Physiological aspects</topic><topic>Recoverin - genetics</topic><topic>Recoverin - metabolism</topic><topic>Tissue Distribution</topic><topic>Toxicity</topic><topic>Transgenic animals</topic><topic>Transgenic mice</topic><topic>Tumors</topic><topic>Uterine Cervical Neoplasms - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ni, S</creatorcontrib><creatorcontrib>Gaggar, A</creatorcontrib><creatorcontrib>Di Paolo, N</creatorcontrib><creatorcontrib>Li, Z Y</creatorcontrib><creatorcontrib>Liu, Y</creatorcontrib><creatorcontrib>Strauss, R</creatorcontrib><creatorcontrib>Sova, P</creatorcontrib><creatorcontrib>Morihara, J</creatorcontrib><creatorcontrib>Feng, Q</creatorcontrib><creatorcontrib>Kiviat, N</creatorcontrib><creatorcontrib>Touré, P</creatorcontrib><creatorcontrib>Sow, P S</creatorcontrib><creatorcontrib>Lieber, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>Biotechnology Research Abstracts</collection><jtitle>Cancer gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ni, S</au><au>Gaggar, A</au><au>Di Paolo, N</au><au>Li, Z Y</au><au>Liu, Y</au><au>Strauss, R</au><au>Sova, P</au><au>Morihara, J</au><au>Feng, Q</au><au>Kiviat, N</au><au>Touré, P</au><au>Sow, P S</au><au>Lieber, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting</atitle><jtitle>Cancer gene therapy</jtitle><stitle>Cancer Gene Ther</stitle><addtitle>Cancer Gene Ther</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>13</volume><issue>12</issue><spage>1072</spage><epage>1081</epage><pages>1072-1081</pages><issn>0929-1903</issn><eissn>1476-5500</eissn><abstract>There is growing evidence from
in vitro
studies that subgroup B adenoviruses (Ad) can overcome the limitations in safety and tumor transduction efficiency seen with commonly used subgroup C serotype 5-based vectors. In this study, we confirm that the expression level of the B-group Ad receptor, CD46, correlates with the grade of malignancy of cervical cancer
in situ
. We also demonstrate the
in vivo
properties of Ad5-based vectors that contain the B-group Ad serotype 35 fiber (Ad5/35) in transgenic mice that express CD46 in a pattern and at a level similar to humans. Upon intravenous and intraperitoneal injection, an Ad5/35 vector did not efficiently transduce normal tissue, but was able to target metastatic or intraperitoneal tumors that express CD46 at levels comparable to human tumors. When an oncolytic Ad5/35-based vector was employed, in both tumor models antitumor effects were observed. Furthermore, injection of Ad5/35 vectors into CD46 transgenic mice caused less innate toxicity than Ad5 vectors. Our data demonstrate that Ad vectors that target CD46 offer advantages over Ad5-based vectors for treatment of cancer.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>16874361</pmid><doi>10.1038/sj.cgt.7700981</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-1903 |
| ispartof | Cancer gene therapy, 2006-12, Vol.13 (12), p.1072-1081 |
| issn | 0929-1903 1476-5500 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19730598 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adenoviridae - genetics Adenovirus Adenoviruses Adenoviruses, Human Animals Antitumor activity Biomedical and Life Sciences Biomedicine CD46 antigen Cell Line, Tumor Cervical cancer Cervix Chemokines - blood Control CpG Islands Cytokines - blood DNA Methylation Expression vectors Female Gene Expression Gene Therapy Genetic aspects Genetic Therapy - methods Genetic Vectors - genetics Genetic Vectors - pharmacokinetics Genetic Vectors - pharmacology Growth Health aspects Humans Inflammation - immunology Inflammation - metabolism Injection Intravenous administration Malignancy Membrane Cofactor Protein - genetics Membrane Cofactor Protein - metabolism Metastases Mice Mice, Inbred C57BL Mice, Transgenic Neoplasms - therapy Oncolysis original-article Physiological aspects Recoverin - genetics Recoverin - metabolism Tissue Distribution Toxicity Transgenic animals Transgenic mice Tumors Uterine Cervical Neoplasms - immunology |
| title | Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T20%3A38%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20adenovirus%20vectors%20containing%20serotype%2035%20fibers%20for%20tumor%20targeting&rft.jtitle=Cancer%20gene%20therapy&rft.au=Ni,%20S&rft.date=2006-12-01&rft.volume=13&rft.issue=12&rft.spage=1072&rft.epage=1081&rft.pages=1072-1081&rft.issn=0929-1903&rft.eissn=1476-5500&rft_id=info:doi/10.1038/sj.cgt.7700981&rft_dat=%3Cgale_proqu%3EA182635971%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217485240&rft_id=info:pmid/16874361&rft_galeid=A182635971&rfr_iscdi=true |